ATE290867T1 - Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten - Google Patents

Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten

Info

Publication number
ATE290867T1
ATE290867T1 AT94903498T AT94903498T ATE290867T1 AT E290867 T1 ATE290867 T1 AT E290867T1 AT 94903498 T AT94903498 T AT 94903498T AT 94903498 T AT94903498 T AT 94903498T AT E290867 T1 ATE290867 T1 AT E290867T1
Authority
AT
Austria
Prior art keywords
antioxidants
diseases
prevention
treatment
free radical
Prior art date
Application number
AT94903498T
Other languages
English (en)
Inventor
Bernard Malfroy-Camine
Michel Baudry
Original Assignee
Eukarion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eukarion Inc filed Critical Eukarion Inc
Application granted granted Critical
Publication of ATE290867T1 publication Critical patent/ATE290867T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
    • C07F13/005—Compounds without a metal-carbon linkage

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Hydrogenated Pyridines (AREA)
AT94903498T 1992-12-07 1993-12-06 Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten ATE290867T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/987,474 US5403834A (en) 1992-12-07 1992-12-07 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
PCT/US1993/011857 WO1994013300A1 (en) 1992-12-07 1993-12-06 Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Publications (1)

Publication Number Publication Date
ATE290867T1 true ATE290867T1 (de) 2005-04-15

Family

ID=25533292

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94903498T ATE290867T1 (de) 1992-12-07 1993-12-06 Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten

Country Status (20)

Country Link
US (2) US5403834A (de)
EP (2) EP1642583A2 (de)
JP (1) JP3502099B2 (de)
KR (1) KR20040004386A (de)
AT (1) ATE290867T1 (de)
AU (1) AU697399B2 (de)
CA (1) CA2150937C (de)
CZ (1) CZ296288B6 (de)
DE (1) DE69333775T2 (de)
GB (2) GB2277873B (de)
HU (1) HU225109B1 (de)
LV (1) LV10924B (de)
NO (1) NO319454B1 (de)
NZ (1) NZ259200A (de)
OA (1) OA10165A (de)
PL (1) PL175446B1 (de)
RU (1) RU2157213C2 (de)
SK (1) SK74595A3 (de)
UA (1) UA27949C2 (de)
WO (1) WO1994013300A1 (de)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5653685A (en) * 1990-10-10 1997-08-05 Lrt, Inc. Method of providing circulation via lung expansion and deflation
USRE36460E (en) * 1990-10-10 1999-12-21 Life Science Holdings, Inc. Method of providing circulation via lung expansion and deflation
US7582786B2 (en) * 1992-12-07 2009-09-01 Eukarion Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5834509A (en) * 1992-12-07 1998-11-10 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5686436A (en) * 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
NZ285648A (en) * 1994-05-13 1999-08-30 Monsanto Co Use of a metal complex as a metal peroxynitrite decomposition catalyst to treat diseases which are affected by accelerated decomposition of peroxynitrite
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
WO1996004311A1 (en) * 1994-08-03 1996-02-15 University Of Alabama At Birmingham Research Foundation Monoclonal antibody to nitrotyrosine, methods for diagnosis and methods for treatment of disease
US5900433A (en) * 1995-06-23 1999-05-04 Cormedics Corp. Vascular treatment method and apparatus
CA2247876A1 (en) * 1996-03-08 1997-09-12 Ronald M. Klatz Liquid ventilation method and apparatus
AU4258097A (en) 1996-09-06 1998-03-26 Duke University Methods for testing compounds for use as therapeutic antioxidants
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
US5834178C1 (en) * 1997-07-09 2002-04-23 Univ Wayne State Flush-storage solution for donor organs
US5829449A (en) * 1997-09-19 1998-11-03 Thione International, Inc. Smoking products containing antioxidants
AT409306B (de) * 1997-10-03 2002-07-25 Hoffmann La Roche Optisch chemischer sensor
DE69813898T2 (de) 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
CA2249778A1 (en) * 1997-12-15 1999-06-15 Bayer Corporation Competitive apo-peroxidase assay
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US7816403B2 (en) * 1998-09-08 2010-10-19 University Of Utah Research Foundation Method of inhibiting ATF/CREB and cancer cell growth and pharmaceutical compositions for same
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
RU2162698C2 (ru) * 1998-10-29 2001-02-10 НИИ психического здоровья Томского научного центра СО РАМН Способ повышения устойчивости к гемолизу эритроцитов и восстановления их поврежденной формы
ATE312103T1 (de) * 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
US6365385B1 (en) 1999-03-22 2002-04-02 Duke University Methods of culturing and encapsulating pancreatic islet cells
US6303355B1 (en) 1999-03-22 2001-10-16 Duke University Method of culturing, cryopreserving and encapsulating pancreatic islet cells
US20040110722A1 (en) * 1999-05-27 2004-06-10 Ornberg Richard L. Modified hyaluronic acid polymers
ES2240101T3 (es) 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
US6179804B1 (en) * 1999-08-18 2001-01-30 Oxypatch, Llc Treatment apparatus for wounds
RU2263672C2 (ru) * 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
US20040047852A1 (en) * 2001-03-02 2004-03-11 Kennedy Thomas Preston Method of treating cancer
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
US6589948B1 (en) 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
WO2002043514A1 (en) * 2000-11-28 2002-06-06 Lorillard Licensing Company, Llc A smoking article including a selective carbon monoxide pump
US6481442B1 (en) 2000-11-28 2002-11-19 Lorillard Licensing Company, Llc Smoking article including a filter for selectively removing carbonyls
US6692458B2 (en) * 2000-12-19 2004-02-17 Edwards Lifesciences Corporation Intra-pericardial drug delivery device with multiple balloons and method for angiogenesis
DK1392328T3 (da) * 2001-01-19 2009-11-09 Nat Jewish Health Medikament til beskyttelse i radioterapi
ITPI20010014A1 (it) * 2001-03-05 2002-09-05 Ivo Pera Composto per filtri per sigarette,o altri articoli da fumo,a base di sostanze antiossidanti ed il filtro cosi'ottenuto
KR100681326B1 (ko) * 2001-04-20 2007-02-15 주식회사 중외제약 신규한 망간-키랄성 화합물 및 그의 이용방법
EP1253131A1 (de) * 2001-04-24 2002-10-30 Aventis Animal Nutrition S.A. Verfahren zur Herstellung eines Xanthophylls
EP1439842A4 (de) * 2001-06-01 2009-09-02 Nat Jewish Med & Res Center Oxidantienfänger zur behandlung von diabetes oder zur verwendung bei der transplantation oder induktion von immuntoleranz
WO2003010143A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co., Ltd. Dialkylhydroxybenzoic acid derivatives containing metal chelating groups and their therapeutic uses
WO2003010154A1 (en) 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. Seleno compounds containing nitrone moiety, their preparation and their therapeutic uses
WO2003010153A1 (en) * 2001-07-26 2003-02-06 Samsung Electronics Co. Ltd. N-alkyl-n-phenylhydroxylamine compounds containing metal chelating groups, their preparation and their therapeutic uses
RU2223790C2 (ru) * 2001-10-25 2004-02-20 ГФУН "Российский научно-исследовательский институт травматологии и ортопедии им. Р.Р. Вредена" Способ стерилизации биологических трансплантатов окисью этилена в жидкой среде
DK1463487T3 (da) * 2001-12-19 2010-08-23 Res Dev Foundation Liposomal afgivelse af vitamin-E baserede forbindelser
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
RU2223493C2 (ru) * 2002-01-22 2004-02-10 В/ч 61469 МО РФ Способ определения вероятной токсичности ксенобиотиков применительно к человеку
WO2003103680A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
US6835387B2 (en) 2002-06-11 2004-12-28 Scimed Life Systems, Inc. Sustained release of superoxide dismutase mimics from implantable or insertable medical devices
US20040132789A1 (en) * 2002-08-22 2004-07-08 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
US20040044220A1 (en) * 2002-08-22 2004-03-04 University Of Florida Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
US7129035B2 (en) * 2002-12-11 2006-10-31 Cryolife, Inc. Method of preserving tissue
RU2246297C2 (ru) * 2003-02-19 2005-02-20 Пятигорская государственная фармацевтическая академия Желатиновые капсулы "гастробиол-цд" на основе клатратов концентрата облепихового масла, обладающие противоязвенным действием
RU2246248C1 (ru) * 2003-06-16 2005-02-20 Ростовский научно-исследовательский онкологический институт МЗ РФ Способ прогнозирования развития метахронного рака молочной железы
WO2005030137A2 (en) * 2003-09-24 2005-04-07 The University Of Toledo, A University Instrumentality Of The State Of Ohio Improving biomechanical performance of irradiated biological material
US20050100537A1 (en) * 2003-11-10 2005-05-12 Evans Gregory S. Methods and kits for reducing cellular damage, inhibiting free radical production, and scavenging free radicals in mammals
US20090099150A1 (en) * 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
DE602006006995D1 (de) * 2005-05-04 2009-07-09 Coty Prestige Lancaster Group Verwendung von freien radikalfängern zum schutz und zur behandlung von durch chemotherapie verursachten haut- und haarschäden
RU2318500C2 (ru) * 2005-10-18 2008-03-10 Общество С Ограниченной Ответственностью "Митотехнология" Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели
RU2290176C1 (ru) * 2005-12-01 2006-12-27 Общество С Ограниченной Ответственностью "Акцент" Устойчивая водно-масляная композиция на основе 6-декапренил-2,3-диметокси-5-метил-1,4-бензохинона и способ ее получения
CN103705947A (zh) * 2006-06-28 2014-04-09 株式会社Ihi 药物、药物引导装置、磁性检测装置和药物设计方法
WO2008070557A2 (en) * 2006-12-01 2008-06-12 Women & Infants Hospital Organometallic complexes as therapeutic agents
RU2364396C2 (ru) * 2007-11-07 2009-08-20 ФГУН "Нижегородский научно-исследовательский институт гигиены и профессиональной патологии" Роспотребнадзора Способ профилактики и коррекции иммунных нарушений, вызываемых токсическими веществами
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
DK2300003T3 (da) 2008-05-23 2014-05-26 Nat Jewish Health Forbindelser til anvendelse i behandling af skade forbundet med eksponering for en alkylerende art
RU2495045C2 (ru) * 2008-11-20 2013-10-10 АйЭйчАй КОРПОРЕЙШН Комплексное соединение самонамагничивающегося металла с саленом
KR101050273B1 (ko) * 2008-11-21 2011-07-19 세종대학교산학협력단 살렌 전이금속 착화합물, 및 그 제조 방법
EP2557155B1 (de) * 2010-04-06 2018-06-13 IHI Corporation Metallsalenkomplex-derivat und herstellungsverfahren dafür
EP2564852B1 (de) * 2010-04-28 2015-02-25 IHI Corporation Wirkstoff gegen gehirntumore
WO2011151978A1 (ja) * 2010-06-01 2011-12-08 株式会社Ihi 蛍光色素材料及びその使用方法
SG192062A1 (en) * 2010-12-21 2013-08-30 Ihi Corp Metal-salen complex compound and production method for same
JP5873656B2 (ja) 2011-06-13 2016-03-01 株式会社Ihi 金属サレン錯体化合物、局所麻酔薬剤及び抗悪性腫瘍薬剤
JP6017766B2 (ja) 2011-07-26 2016-11-02 株式会社Ihi 新規な金属サレン錯体化合物の抗がん剤
RU2595840C2 (ru) * 2011-10-04 2016-08-27 АйЭйчАй КОРПОРЕЙШН Лекарственное средство, чувствительное к комплексному соединению металл-сален, и система регуляции интракорпорального свойства для комплексного соединения металл-сален
JP6046338B2 (ja) * 2011-10-27 2016-12-14 株式会社Ihi ラジカル抑制剤
BR112014016497B1 (pt) * 2012-01-05 2021-02-23 Pledpharma Ab complexos de metal misturados, composição farmacêutica compreendendo os mesmos, métodos de produção e uso
CN108030926B (zh) * 2017-12-15 2021-07-13 武汉工程大学 一种具有高的SOD酶活性的Salen型锰配合物-壳聚糖复合材料及其制备方法
RU2699040C1 (ru) * 2018-07-23 2019-09-03 Федеральное государственное бюджетное учреждение науки "Уральский научно-практический центр радиационной медицины Федерального медико-биологического агентства" (ФГБУН УНПЦ РМ ФМБА России) Способ экстренной профилактики и лечения острой лучевой болезни (варианты)
EP4788342A1 (de) * 2023-10-03 2026-08-12 Aarhus Universitet Antioxidative mikrogele für lebererkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
US5106841A (en) * 1986-05-13 1992-04-21 Chai-Tech Corporation Antiviral compositions and method for their use
US5223538A (en) * 1987-03-31 1993-06-29 Duke University Superoxide dismutase mimic
ATE213663T1 (de) * 1991-08-26 2002-03-15 Res Corp Technologies Inc Herstellung von epoxchromanen mit einem chiralen katalysator
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease

Also Published As

Publication number Publication date
GB2277873A (en) 1994-11-16
NO952237D0 (no) 1995-06-06
WO1994013300A1 (en) 1994-06-23
CZ296288B6 (cs) 2006-02-15
CA2150937A1 (en) 1994-06-23
RU2157213C2 (ru) 2000-10-10
CA2150937C (en) 2007-08-14
JPH08504211A (ja) 1996-05-07
HU225109B1 (en) 2006-06-28
NO952237L (no) 1995-08-01
EP0746321B1 (de) 2005-03-16
GB2305107A (en) 1997-04-02
CZ144295A3 (en) 1996-10-16
GB2305107B (en) 1997-05-14
US5403834A (en) 1995-04-04
DE69333775D1 (de) 2005-04-21
HU9501644D0 (en) 1995-08-28
AU5741994A (en) 1994-07-04
EP0746321A1 (de) 1996-12-11
JP3502099B2 (ja) 2004-03-02
GB2277873B (en) 1997-05-14
GB9415050D0 (en) 1994-09-14
PL309334A1 (en) 1995-10-02
DE69333775T2 (de) 2006-04-06
NZ259200A (en) 1997-06-24
PL175446B1 (pl) 1998-12-31
US5827880A (en) 1998-10-27
NO319454B1 (no) 2005-08-15
OA10165A (en) 1996-12-18
SK74595A3 (en) 1996-05-08
EP1642583A2 (de) 2006-04-05
HUT72967A (en) 1996-06-28
EP0746321A4 (de) 2001-05-09
UA27949C2 (uk) 2000-10-16
KR20040004386A (ko) 2004-01-13
AU697399B2 (en) 1998-10-08
LV10924B (en) 1996-10-20
GB9621087D0 (en) 1996-11-27
LV10924A (lv) 1995-12-20

Similar Documents

Publication Publication Date Title
DE69333775D1 (de) Synthetische katalytische freie radikalfänger, verwendbar als antioxidantien zur prävention und therapie von krankheiten
DE59310327D1 (de) Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
CA2223510A1 (en) Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE59606784D1 (de) Verwendung von boswelliasäure und ihren derivaten zur hemmung der normalen und gesteigerten leukozytenelastase- oder plasminaktivität
ES2102010T3 (es) Composiciones farmaceuticas de bacteriocina y su utilizacion para el tratamiento de trastornos gastrointestinales.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
GR3032224T3 (en) Therapeutic agent for threatened abortion.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DE69314586D1 (de) Arzneimittelzusammensetzung enthaltend TCF-II
DE59304087D1 (de) Placentaextrakt und Verfahren zu seiner Herstellung
CA2140010A1 (en) Blood coagulation normalizer containing tcf-ii as active ingredient
EP0444899A3 (en) Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen
ATE136776T1 (de) Verwendung von heptastigmin zur behandlung der zerebralen ictus
ATE79759T1 (de) Kombinationspraeparat zur behandlung von nervenzell-und nervenfasererkrankungen und verletzungen.
RU94001389A (ru) Способ лечения псориаза

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties